Abstract

Sodium glucose transporter-2 inhibitors dapagliflozin and empagliflozin are useful to prevent hospitalizations and mortality among heart failure with reduced ejection fraction (HFrEF) patients. However, no clinical trials have been performed to assess comparative performance of these drugs. The objective of this project was to compare the cost-effectiveness of dapagliflozin and empagliflozin for treatment of HFrEF.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call